These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 19246251)
1. Substrate for development of atrial fibrillation in patients with congestive heart failure: are we close to the answer? Platonov PG Heart Rhythm; 2009 Apr; 6(4):452-3. PubMed ID: 19246251 [No Abstract] [Full Text] [Related]
2. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Workman AJ; Pau D; Redpath CJ; Marshall GE; Russell JA; Norrie J; Kane KA; Rankin AC Heart Rhythm; 2009 Apr; 6(4):445-51. PubMed ID: 19324301 [TBL] [Abstract][Full Text] [Related]
3. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Makkar KM; Sanoski CA; Spinler SA Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795 [TBL] [Abstract][Full Text] [Related]
6. [Atrial fibrillation in patients with heart failure. Pathophysiological concepts and therapeutic options]. Boldt LH; Rolf S; Dietz R; Haverkamp W Dtsch Med Wochenschr; 2008 Nov; 133(45):2349-54. PubMed ID: 18958832 [No Abstract] [Full Text] [Related]
7. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Boldt LH; Rolf S; Huemer M; Parwani AS; Luft FC; Dietz R; Haverkamp W Am Heart J; 2008 May; 155(5):890-5. PubMed ID: 18440338 [TBL] [Abstract][Full Text] [Related]
8. Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Shi H; Wang H; Li D; Nattel S; Wang Z Cell Physiol Biochem; 2004; 14(1-2):31-40. PubMed ID: 14976404 [TBL] [Abstract][Full Text] [Related]
9. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Cha TJ; Ehrlich JR; Zhang L; Shi YF; Tardif JC; Leung TK; Nattel S Circulation; 2004 Jan; 109(3):412-8. PubMed ID: 14718405 [TBL] [Abstract][Full Text] [Related]
10. [Dofetilide in patients with chronic heart failure and left ventricular dysfunction]. Latini R Ital Heart J Suppl; 2000 Mar; 1(3):427-8. PubMed ID: 10815277 [No Abstract] [Full Text] [Related]
11. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Hanna IR; Heeke B; Bush H; Brosius L; King-Hageman D; Dudley SC; Beshai JF; Langberg JJ Heart Rhythm; 2006 Aug; 3(8):881-6. PubMed ID: 16876733 [TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. Nieuwlaat R; Eurlings LW; Cleland JG; Cobbe SM; Vardas PE; Capucci A; López-Sendòn JL; Meeder JG; Pinto YM; Crijns HJ J Am Coll Cardiol; 2009 May; 53(18):1690-8. PubMed ID: 19406345 [TBL] [Abstract][Full Text] [Related]
13. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. Liu E; Xu Z; Li J; Yang S; Yang W; Li G Int J Cardiol; 2011 Feb; 146(3):364-70. PubMed ID: 19732978 [TBL] [Abstract][Full Text] [Related]